BlueCrest Capital Management’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-84,381
Closed -$10.2M 367
2023
Q1
$10.2M Buy
84,381
+15,366
+22% +$1.77M 0.33% 48
2022
Q4
$7.92M Buy
69,015
+55,925
+427% +$6.16M 0.21% 55
2022
Q3
$1.32M Buy
+13,090
New +$1.38M 0.04% 126
2022
Q2
Sell
-33,302
Closed -$3.88M 277
2022
Q1
$3.88M Sell
33,302
-1,982
-6% -$229K 0.13% 108
2021
Q4
$4.05M Buy
+35,284
New +$4.02M 0.13% 131
2020
Q3
Sell
-24,726
Closed -$2.59M 349
2020
Q2
$2.59M Buy
+24,726
New +$2.65M 0.14% 113

Other funds holding BSX.PRA

BlueCrest Capital Management's BSX.PRA Position: Q2 2023 in Review

BlueCrest Capital Management sold out of Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A (BSX.PRA) in Q2 2023, closing a stake of 84,381 shares — an estimated $10.2M sold.

BlueCrest Capital Management first reported a position in BSX.PRA in Q2 2020 and held it in 6 quarters. The position peaked at $10.2M in Q1 2023. 1 fund tracked by Wall St. Rank holds BSX.PRA as of Q2 2023.

  • BlueCrest Capital Management reported no remaining Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position as of Q2 2023 after selling out during the quarter.
  • BlueCrest Capital Management sold 84,381 Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A shares in Q2 2023, an estimated $10.2M.
  • BlueCrest Capital Management first reported a position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A in Q2 2020 and held it in 6 quarters.
  • BlueCrest Capital Management's Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position peaked at $10.2M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A as of Q2 2023.

Based on BlueCrest Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.